262 related articles for article (PubMed ID: 32893189)
1. Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
Paluch-Shimon S; Cherny NI; de Vries EGE; Dafni U; Piccart MJ; Latino NJ; Cardoso F
ESMO Open; 2020 Sep; 5(5):e000743. PubMed ID: 32893189
[TBL] [Abstract][Full Text] [Related]
2. Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.
Knapen DG; Cherny NI; Zygoura P; Latino NJ; Douillard JY; Dafni U; de Vries EGE; de Groot DJ
ESMO Open; 2020 Sep; 5(5):e000681. PubMed ID: 32893188
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer.
Sapir E; Cherny NI; Ennis RD; Smith BD; Smith GL; Marks LB; Corn BW
ESMO Open; 2023 Jun; 8(3):101206. PubMed ID: 37236087
[TBL] [Abstract][Full Text] [Related]
4. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
Kiesewetter B; Dafni U; de Vries EGE; Barriuso J; Curigliano G; González-Calle V; Galotti M; Gyawali B; Huntly BJP; Jäger U; Latino NJ; Malcovati L; Oosting SF; Ossenkoppele G; Piccart M; Raderer M; Scarfò L; Trapani D; Zielinski CC; Wester R; Zygoura P; Macintyre E; Cherny NI;
Ann Oncol; 2023 Sep; 34(9):734-771. PubMed ID: 37343663
[TBL] [Abstract][Full Text] [Related]
5. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.
Kiesewetter B; Cherny NI; Boissel N; Cerisoli F; Dafni U; de Vries EGE; Ghia P; Gökbuget N; González-Calle V; Huntly B; Jäger U; Latino NJ; Douillard JY; Malcovati L; Mateos MV; Ossenkoppele GJ; Porkka K; Raderer M; Ribera JM; Scarfò L; Wester R; Zygoura P; Sonneveld P
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958292
[TBL] [Abstract][Full Text] [Related]
6. ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Cherny NI; Dafni U; Bogaerts J; Latino NJ; Pentheroudakis G; Douillard JY; Tabernero J; Zielinski C; Piccart MJ; de Vries EGE
Ann Oncol; 2017 Oct; 28(10):2340-2366. PubMed ID: 28945867
[TBL] [Abstract][Full Text] [Related]
7. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
Gyawali B; de Vries EGE; Dafni U; Amaral T; Barriuso J; Bogaerts J; Calles A; Curigliano G; Gomez-Roca C; Kiesewetter B; Oosting S; Passaro A; Pentheroudakis G; Piccart M; Roitberg F; Tabernero J; Tarazona N; Trapani D; Wester R; Zarkavelis G; Zielinski C; Zygoura P; Cherny NI
ESMO Open; 2021 Jun; 6(3):100117. PubMed ID: 33887690
[TBL] [Abstract][Full Text] [Related]
8. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit.
Oosting SF; Barriuso J; Bottomley A; Galotti M; Gyawali B; Kiesewetter B; Latino NJ; Martinelli F; Pe M; Pentheroudakis G; Roitberg F; Vachon H; de Vries EGE; Piccart M; Cherny NI;
Ann Oncol; 2023 Apr; 34(4):431-439. PubMed ID: 36549587
[TBL] [Abstract][Full Text] [Related]
9. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Cherny NI; Sullivan R; Dafni U; Kerst JM; Sobrero A; Zielinski C; de Vries EG; Piccart MJ
Ann Oncol; 2015 Aug; 26(8):1547-73. PubMed ID: 26026162
[TBL] [Abstract][Full Text] [Related]
10. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
Del Paggio JC; Azariah B; Sullivan R; Hopman WM; James FV; Roshni S; Tannock IF; Booth CM
Ann Oncol; 2017 Jan; 28(1):157-162. PubMed ID: 27742650
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores.
Broekman KE; Jalving M; van Tinteren H; Sessa C; Reyners AKL
Cancer Treat Rev; 2018 Sep; 69():233-242. PubMed ID: 30098485
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
Broekman KE; van Kruchten M; van Tinteren H; Sessa C; Jalving M; Reyners AKL
ESMO Open; 2021 Aug; 6(4):100229. PubMed ID: 34371383
[TBL] [Abstract][Full Text] [Related]
13. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.
Grössmann N; Del Paggio JC; Wolf S; Sullivan R; Booth CM; Rosian K; Emprechtinger R; Wild C
Eur J Cancer; 2017 Sep; 82():66-71. PubMed ID: 28648700
[TBL] [Abstract][Full Text] [Related]
14. Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1.
García-Fumero R; Fernández-López C; Calleja-Hernández MÁ; Expósito-Hernández J
Acta Oncol; 2021 Sep; 60(9):1225-1232. PubMed ID: 34184595
[TBL] [Abstract][Full Text] [Related]
15. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
[TBL] [Abstract][Full Text] [Related]
16. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.
Kiesewetter B; Raderer M; Prager GW; Fuereder T; Marosi C; Preusser M; Krainer M; Locker GJ; Brodowicz T; Zielinski CC
ESMO Open; 2017; 2(3):e000166. PubMed ID: 28761758
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
[TBL] [Abstract][Full Text] [Related]
18. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1.
Pichler M; Steyrer J
ESMO Open; 2021 Aug; 6(4):100198. PubMed ID: 34175674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
